New Equity Report

Date: 2021-11-03

Redeye AB has revisited the Alzinova equity story with the initiation of clinical trials with ALZ-101, our vaccine candidate in Alzheimer’s, an indication with a vast unmet medical need. "Now is the time when the case could start to heat up."

Click the link below to read the full updated equity report.

Redeye equity report